Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 11, 2004, Pages 4328-4331

  DiCenzo, Robert ^a,b,c   Peterson, Derick ^b   Cruttenden, Kim ^b   Morse, Gene ^a   Riggs, Garret ^b   Gelbard, Harris ^b   Schifitto, Giovanni ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VALPROIC ACID; ZALCITABINE; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STEADY STATE;

ADULT; ANTI-HIV AGENTS; ANTICONVULSANTS; AREA UNDER CURVE; COGNITION DISORDERS; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HIV INFECTIONS; HUMANS; MALE; OXAZINES; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; VALPROIC ACID;

EID: 7244238106     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.11.4328-4331.2004     Document Type: Article

References (37)

1. Acosta, E., J. Gerber, and The Adult Pharmacology Committee of the AIDS Clinical Trials Group. 2002. Group position paper on therapeutic drug monitoring of antiviral agents. AIDS Res. Hum. Retrovir. 18(12):825-834.
2. Adle-Biassette, H., Y. Levy, M. Colombel, F. Poron, S. Natchev, and C. Keohane. 1995. Neuronal apoptosis in HIV infection in adults. Neuropathol. Appl. Neurobiol. 21:218-227.
3. Anderson, G. 1998. A mechanistic approach to antiepileptic drug interactions. Ann. Pharmacother. 32:554-563.
4. Anderson, G. D., B. E. Gidal, E. Kantor, and A. J. Wilensky. 1994. Lorazepam-valproic acid interaction: studies in normal subjects and isolated perfused rat liver. Epilepsia 35:221-225.
5. Burger, D. M., P. W. Hugen, P. Reiss, I. Gyssens, F. K. Schneider, G. Schreij, K. Brinkman, C. Richter, J. Prins, R. Aarnoutse, and J. M. Lange. 2003. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS 17(8):1157-1165.
6. Crawford, P., D. Chadwick, P. Cleland, J. Tjia, and A. Cowie. 1986. The lack of effect of valproate on the pharmacokinetics of oral contraceptive steroids. Contraception 33:23-29.
7. Cross, D. A., D. R. Alessi, P. Cohen, M. Andjelkovic, and B. Hemmings. 1995. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785-789.
8. Crowder, R., and R. Freeman. 1998. Phosphatidylinositol 3-kinase and Akt protein kinase are necessary and sufficient for the survival of nerve growth factor-dependent sympathetic neurons. J. Neurosci. Res. 18:2933-2943.
9. DiCenzo, R., A. Forrest, K. E. Squires, S. M. Hammer, M. A. Fischl, H. Wu, R. Cha, G. D. Morse, and The Adult AIDS Clinical Trials Group Protocol 368/886 Study Team. 2003. Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 47:1929-1935.
10. Don, H., K. Birusingh, I. Faraci, S. Gorantla, L. Y. Poluektova, and S. Maggirwar, et al. 2003. Neuroprotective activities of sodium valproate in a murine model of HIV-1 encephalitis. J. Neurosci., 23:9162-9170.
11. Dudek, H., S. R. Datta, T. F. Franke, M. J. Birnbaum, R. Yao, and G. M. Cooper. 1997. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275:661-665.
12. Everall, I., P. Luthert, and P. Lantos. 1991 Neuronal loss in the frontal cortex in HIV infection. Lancet 3357:1119-1121.
13. Fletcher, C. V., P. L. Anderson, T. N. Kakuda, T. W. Schacker, K. Henry, C. R. Gross, and R. C. Brundage. 2002. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 16(4):551-560.
14. Flexner, C., and S. Piscitelli. 2002. Concentration-targeted therapy and the future of HIV management. AIDS 16(Suppl. 1):S1-S3.
15. Gelbard, H. A., H. S. L. M. Nottet, S. Swindells, M. Jett, K. A. Dzenko, P. Genis, R. White, L. Wang, Y.-B. Choi, D. Zhang, S. A. Lipton, W. W. Tourtellotte, S. G. Epstein, and H. E. Gendelman. 1994. Platelet-activating factor: a candidate human immunodeficiency virus type 1-induced neurotoxin. J. Virol. 68:4628-4635.
16. Gelbard, H. A., H. J. James, L. R. Sharer, S. W. Perry, Y. Saito, and A. M. Kazee. 1995. Apoptotic neurons in brains from pediatric patients with HIV-1 encephalitis and progressive encephalopathy. Neuropathol. Appl. Neurobiol. 21(3):208-217.
17. Hillebrand, G., L. A. Castro, W. van Scheidt, D. Beukelmann, W. Land, and D. Schmidt. 1987. Valproate for epilepsy in renal transplant recipients receiving cyclosporine. Transplantation 43:915-916.
18. Keil, K., V. A. Frerichs, R. DiFrancesco, and G. D. Morse. 2003. Reverse phase high performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite, M8 ritonavir, and saquinavir in heparinized human plasma. Ther. Drug Monit. 25:340-346.
19. Ketzler, S., S. Weis, H. Haug, and H. Budka. 1990. Neuronal loss in the frontal cortex in HIV infection. Acta Neuropathol. 80:92-94.
20. Maggirwar, S. B., N. Tong, S. Ramirez, H. A. Gelbard, and S. Dewhurst. 1999. HIV-1 Tat-mediated activation of glycogen synthase kinase-3 beta contributes to Tat-mediated neurotoxicity. J. Neurochem. 73:578-586.
21. Magnuson, D. S. K., B. E. Knudson, J. D. Geiger, R. M. Brownstone, and A. Nath. 1995. Human immunodeficiency virus type 1 tat activates non-N-methyl-D-aspartate excitatory amino acid receptors and causes neurotoxicity. Ann. Neurol. 37:373-380.
22. McNamara, J. 2001. Drugs effective in the therapy of epilepsies, p. 536-537. In A. Goodman Gilman (ed.), The pharmacological basis of therapeutics. McGraw-Hill, New York, N.Y.
23. Miller, T. M., M. G. Tansey, E. M. Johnson, Jr., and D. J. Creedon. 1997. Inhibition of phosphatidylinositol 3-kinase activity blocks depolarization- and insulin-like growth factor I-mediated survival of cerebellar granule cells. J. Biol. Chem. 272:9847-9853.
24. New, D. R., S. B. Maggirwar, L. G. Epstein, S. Dewhurst, and H. A. Gelbard. 1998. HIV-1 Tat induces neuronal death via tumor necrosis factor-alpha and activation of non-N-methyl-D-aspartate receptors by a NFκB-independent mechanism. J. Biol. Chem. 273:17852-17858.
25. Perry, S. W., J. A. Hamilton, L. W. Tjoelker, G. Dbaibo, K. A. Dzenko, and L. G. Epstein. 1999. Platelet-activating factor receptor activation: an initiator step in HIV-1 neuropathogenesis. J. Biol. Chem. 273:17660-17664.
26. Petito, C., and B. Roberts. 1995 Evidence of apoptotic cell death in HIV encephalitis. Am. J. Pathol. 146:1121-1130.
27. Philippon, V., C. Vellutini, D. Gambarelli, G. Harkiss, G. Arbuthnott, and D. Metzger. 1994. The basic domain of the lentiviral Tat protein is responsible for damages in mouse brain: involvement in cytokines. Virology 205:519-529.
28. Raffanti, S., and D. Haas 2001. Antimicrobial agents: antiviral agents, p. 1364-1373. In A. Goodman Gilman (ed.), The pharmacological basis of therapeutics. McGraw-Hill, New York, N.Y.
29. Sabatier, J.-M., E. Vives, K. Mabrouk, A. Benjouad, H. Rochat, A. Duval, B. Hue, and E. Bahraoui. 1991. Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1. J. Virol. 65:961-967.
30. Sacktor, N., M. P. McDermott, K. Marder, G. Schifitto, O. A. Selnes, J. C. McArthur, Y. Stern, S. Albert, D. Palumbo, K. Kieburtz, J. A. De Marcaida, B. Cohen, and L. Epstein. 2002. HIV-associated cognitive impairment before and after the advent of combination therapy. J. Neurovirol. 8:136-142.
31. Scheyer, R., and R. Mattson. 1995. Valproate: interactions with other drugs, p. 621-631. In R. Levy, H. Mattson, and B. Meldrum (ed.), Antiepileptic drugs. Raven Press, New York, N.Y.
32. Shi, B., U. De Girolami, J. He, S. Wand, A. Lorenzo, and J. Busciglio. 1996. Apoptosis induced by HIV-1 infection of the central nervous system. J. Clin. Investig. 98:1979-1990.
33. Smith, P., R. DiCenzo, and G. Morse. 2001. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin. Pharmacokinet. 40(12):893-905.
34. Trapnell, C. B., R. W. Kleckner, C. Jamison, and J. M. Collins. 1998. Glucuronidation of 3′-azido-3′-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid. Antimicrob. Agents Chemother. 42: 1592-1596.
35. Weeks, B. S., D. M. Liebermann, B. Johnson, E. Roque, M. Green, and P. Lowenstein. 1995. Neurotoxicity of the human immunodeficiency virus type 1 tat transactivator to PC12 cells requires the Tat amino acid 49 to 58 basic domain. J. Neurosci. Res. 42:34-40.
36. Yao, R., and G. Cooper. 1995. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 267:2003-2006.
37. Yuen, A. 1995. Lamotrigene: interactions with other drugs, p. 883-887. In B. Meldrum (ed.), Antiepileptic drugs. Raven Press, New York, N.Y.